Comparative Pharmacology
Head-to-head clinical analysis: FELBATOL versus LYRICA CR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FELBATOL versus LYRICA CR.
FELBATOL vs LYRICA CR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Felbamate is a GABA receptor agonist and modulates NMDA receptor activity, though its exact mechanism is not fully understood. It appears to enhance GABA-mediated inhibition and inhibit voltage-gated sodium channels, reducing neuronal excitability.
Binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing calcium influx and inhibiting excitatory neurotransmitter release (e.g., glutamate, norepinephrine, substance P).
1200-3600 mg/day orally in 3-4 divided doses; initial titration recommended.
Initial 75 mg orally twice daily (150 mg/day), or 50 mg three times daily (150 mg/day). Based on efficacy and tolerability, may increase to 150 mg twice daily (300 mg/day) after 1 week, then to 225 mg twice daily (450 mg/day) if needed. Maximum dose 450 mg/day. Take with food. Administer whole; do not split, crush, or chew.
None Documented
None Documented
20-23 hours; steady state reached within 3-5 days; may be prolonged in hepatic impairment.
6.3 hours (mean terminal elimination half-life); correlates with creatinine clearance, prolonged in renal impairment.
Renal: 40-50% unchanged; Hepatic metabolism accounts for ~50% with glucuronidation and oxidation; minimal biliary/fecal excretion (<5%).
Primarily renal excretion as unchanged drug (98-99% of absorbed dose); <0.1% biliary/fecal.
Category C
Category C
Anticonvulsant
Anticonvulsant